Kleinostheim, 05.12.2012 – curasan AG, listed on the General Standard (ISIN: DE 000 549 453 8), has introduced its new bone regeneration material CERASORB® Ortho Paste to the German and European marke...
Results from a pre-specified pooled analysis of the RECORD clinical trial program confirmed that the novel oral anticoagulant Xarelto ® (rivaroxaban), taken as one tablet, once-daily, was superior to...
Health Canada has just approved Xarelto® (rivaroxaban) for the prevention of venous thromboembolic events (VTE) in patients who have undergone elective total hip or total knee replacement surgery. Thi...
Kleinostheim, Germany, September 4 th , 2009 – curasan AG, listed on the General Standard of Deutsche Börse AG as ISIN: DE 000 549 453 8, has just received a grant of €1.48 million from the German Fed...
A new study was presented at the 4 th Annual Congress of the German Spine Society in Munich - it demonstrated the long-term effect of Curavisc ® in the treatment of chronic facet syndrome
27% of Medical Device Industry Executives Will "Definitely" Pursue New Employment in 2010; 28% Indicate "Strong Possibility." Only 22% are committed to staying in current role. According to a poll of...
Already a highly sought after physician who works with the Tampa Bay Buccaneers and US Olympic Team, Coastal Orthopedics surgeon Daniel Lamar, MD is bringing his sports medicine expertise to the Manat...
curasan Inc., the north American subsidiary of exchange listed curasan AG, Germany, has signed an exclusive supply agreement with TransCorp Spine Inc., Michigan, USA, for Cerasorb ® Ortho block forms...
curasan AG has signed an agreement with Stryker S.A., Montreux, Switzerland, to sell and market bone replacement and regeneration materials for different orthopedic indications
